2-(2-溴乙基)吡啶 | 39232-04-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(2-溴乙基)吡啶
• 中文别名: 2-溴乙基吡啶
• 英文名称: 2-(2-bromoethyl)pyridine
• 英文别名: β-bromoethylpyridine；1-Brom-2-(2-pyridyl)-ethan；2-bromoethylpyridine；2-(2-bromo-ethyl)-pyridine；2-(2-Brom-aethyl)-pyridin
• CAS: 39232-04-7
• 化学式: C₇H₈BrN
• mdl: MFCD08274972
• 分子量: 186.051
• InChiKey: VZWCPLGFXOCGLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(2-Bromoethyl)pyridine hydrobromide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(2-Bromoethyl)pyridine hydrobromide
CAS number: 39232-04-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8BrN.BrH
Molecular weight: 267.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(2-溴乙基)吡啶 在 sodium azide 、 trans-RuCl(phenpyra-Me)(PPh₃)₂PF₆ 、 sodium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 12.0h， 生成 2-(2-甲基氨基乙基)吡啶
  参考文献：
  名称：

  使用甲醇和叠氮化钠作为C1和N1来源选择性合成单和二甲基胺

  摘要：

  报道了使用甲醇作为甲基化剂，由有机叠氮化物介导的Ru（II）络合物介导的各种N，N-二甲基和N-单甲基胺的合成。该方法已成功应用于溴化物衍生物和叠氮化钠在甲醇中的一锅法反应。明显地，通过控制反应时间，几个N-单甲基化和N，N选择性合成-二甲基化胺。通过与不同有机叠氮化物的制备规模反应以及抗眩晕药倍他司汀的合成，揭示了该串联过程的实际适用性。进行了一些动力学实验和DFT研究，以了解这种转化的机理。

  DOI：

  10.1039/c8gc00863a
• 作为产物：
  描述：

  2-(2-溴乙基)吡啶氢溴酸盐 在 sodium hydroxide 作用下， 以95%的产率得到2-(2-溴乙基)吡啶
  参考文献：
  名称：

  Spiro Derivatives of Tetrahydrothiophene. Synthesis of the Quinolizidine <3-spiro-2′> tetrahydrothiophene System Using Solid/Liquid or Liquid/Liquid Phase-Transfer Catalysis

  摘要：

  4-氧代八氢喹啉<3-螺-2'>四氢噻吩1',1'-二氧化物可以通过两条独立的途径从2-氰基四氢噻吩合成，两者均使用相转移催化：第一条途径涉及在PTC条件下对2-氰基四氢噻吩进行烷基化，第二条途径则是使用2-氯乙基哌啶与2-氯羰基四氢噻吩进行N-酰化，最后在PTC条件下进行环烷基化。得到两个螺旋化合物的立体异构体。

  DOI：

  10.1055/s-1987-33430

文献信息

• [EN] MODULATORS OF TREX1<br/>[FR] MODULATEURS DE TREX1
  申请人：CONSTELLATION PHARMACEUTICALS INC

  公开号：WO2020118133A1

  公开（公告）日：2020-06-11

  Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositons thereof, which are useful for treating a variety of conditions associated with TREX1.

  提供的是Formula (I)的化合物及其药用盐和组合物，可用于治疗与TREX1相关的各种疾病。
• [EN] PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS D'ACIDE PYRIDIN-3-YLE ACÉTIQUE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK NO 5 LTD

  公开号：WO2018127800A1

  公开（公告）日：2018-07-12

  Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. (I)

  公开了公式I的化合物，包括药用可接受的盐、包含这些化合物的药物组合物、制备这些化合物的方法，以及它们在抑制HIV整合酶和治疗HIV或艾滋病感染者中的用途。
• [EN] PYRAZOLE DERIVATIVES HAVING ACTIVITY AGAINST PAIN<br/>[FR] DÉRIVÉS DE PYRAZOLE AYANT UNE ACTIVITÉ CONTRE LA DOULEUR
  申请人：ESTEVE LABOR DR

  公开号：WO2018001973A1

  公开（公告）日：2018-01-04

  The present invention relates to pyrazole derivatives of formula (I) having pharmacological activity towards the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated calcium channel, in particular having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated calcium channel and the μ-opioid receptor. The present invention also relates to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

  本发明涉及具有药理活性的式（I）的吡唑衍生物，特别是对于电压门控钙通道的α2δ亚基，特别是对于电压门控钙通道的α2δ-1亚基，具有双重药理活性，特别是对于电压门控钙通道的α2δ亚基，特别是对于电压门控钙通道的α2δ-1亚基，以及μ-阿片受体。本发明还涉及制备这类化合物的方法，包括它们的药物组合物，以及它们在治疗中的使用，特别是用于疼痛治疗。
• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120277224A1

  公开（公告）日：2012-11-01

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的杂环化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制PAS激酶（PASK）在人类或动物主体中活性的方法，用于治疗疾病，如糖尿病。
• [EN] OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS<br/>[FR] OXADIAZOLONES EN TANT QU'INHIBITEURS DE CANAL POTENTIEL RÉCEPTEUR TRANSITOIRE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018096159A1

  公开（公告）日：2018-05-31

  The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

  该发明涉及式(I)的化合物及其药用可接受的盐。此外，本发明涉及制备方法和使用式(I)的化合物的方法，以及含有这种化合物的药物组合物。这些化合物可能在治疗由TRPA1介导的疾病和症状，如疼痛方面有用。